DOP2014000011A - Compuesto inhibidor de la señalización de la trayectoria notch - Google Patents

Compuesto inhibidor de la señalización de la trayectoria notch

Info

Publication number
DOP2014000011A
DOP2014000011A DO2014000011A DO2014000011A DOP2014000011A DO P2014000011 A DOP2014000011 A DO P2014000011A DO 2014000011 A DO2014000011 A DO 2014000011A DO 2014000011 A DO2014000011 A DO 2014000011A DO P2014000011 A DOP2014000011 A DO P2014000011A
Authority
DO
Dominican Republic
Prior art keywords
notch
signaling
trajectory
inhibitor compound
compound
Prior art date
Application number
DO2014000011A
Other languages
English (en)
Spanish (es)
Inventor
Gregory Alan Stephenson
Philip Arthur Hipskind
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2014000011A publication Critical patent/DOP2014000011A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DO2014000011A 2011-07-27 2014-01-22 Compuesto inhibidor de la señalización de la trayectoria notch DOP2014000011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
DOP2014000011A true DOP2014000011A (es) 2014-07-31

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000011A DOP2014000011A (es) 2011-07-27 2014-01-22 Compuesto inhibidor de la señalización de la trayectoria notch

Country Status (36)

Country Link
US (1) US8569286B2 (https=)
EP (1) EP2736920B1 (https=)
JP (1) JP6027110B2 (https=)
KR (1) KR101578309B1 (https=)
CN (1) CN103732612B (https=)
AP (1) AP4080A (https=)
AR (1) AR087107A1 (https=)
AU (1) AU2012287251B2 (https=)
BR (1) BR112014001600B1 (https=)
CA (1) CA2841178C (https=)
CL (1) CL2014000175A1 (https=)
CO (1) CO6862159A2 (https=)
CR (1) CR20140036A (https=)
CY (1) CY1116645T1 (https=)
DK (1) DK2736920T3 (https=)
DO (1) DOP2014000011A (https=)
EA (1) EA023044B1 (https=)
EC (1) ECSP14013179A (https=)
ES (1) ES2544937T3 (https=)
GT (1) GT201400012A (https=)
HR (1) HRP20150771T1 (https=)
HU (1) HUE027534T2 (https=)
IL (1) IL229988A (https=)
JO (1) JO3148B1 (https=)
MA (1) MA35611B1 (https=)
ME (1) ME02171B (https=)
MX (1) MX356536B (https=)
MY (1) MY184303A (https=)
PE (1) PE20141061A1 (https=)
PH (1) PH12014500215B1 (https=)
PL (1) PL2736920T3 (https=)
PT (1) PT2736920E (https=)
RS (1) RS54135B1 (https=)
SI (1) SI2736920T1 (https=)
TW (1) TWI568730B (https=)
WO (1) WO2013016081A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
EP3442528B1 (en) * 2016-04-12 2021-05-26 Eli Lilly and Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer
JP6911047B2 (ja) * 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法
JP7194022B2 (ja) 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Notch阻害剤とPD-1またはPD-L1阻害剤との併用療法
SG11201901325UA (en) * 2016-08-31 2019-03-28 Lilly Co Eli Dosage regimen for treatment of solid tumors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
JP7208137B2 (ja) 2016-12-09 2023-01-18 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MX2020004568A (es) * 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
KR20210005714A (ko) * 2018-05-06 2021-01-14 아얄라 파마큐티컬즈 아이엔씨. 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
CA3114113A1 (en) 2018-10-02 2020-04-09 Frequency Therapeutics, Inc. Pharmaceutical compositions and methods related to otic therapeutic agents
US20220175776A1 (en) 2019-04-08 2022-06-09 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
TW202334164A (zh) 2022-01-12 2023-09-01 美商戴納立製藥公司 (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001232A3 (en) * 1996-12-23 2001-02-28 Elan Pharmaceuticals Inc San F Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds
JP2002518481A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチドの放出および/またはその合成を阻害するための化合物
WO1999067221A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
EP1592684B1 (en) 2003-02-04 2008-07-30 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
KR100838852B1 (ko) 2003-09-09 2008-06-16 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
SI1673347T1 (sl) 2003-10-06 2015-10-30 F. Hoffmann - La Roche Ag Substituirani derivati dibenzo-azepina in benzo-diazepina, ki so uporabni kot inhibitorji gama-sekretaze
ES2398531T3 (es) 2006-03-27 2013-03-20 F. Hoffmann-La Roche Ag Derivados de malonamida como inhibidores de gamma secretasa
KR101150574B1 (ko) * 2007-02-02 2012-05-30 에프. 호프만-라 로슈 아게 6-옥소-6,7-다이하이드로-5h-다이벤조[b,d]아제핀-7-일 유도체
MA33076B1 (fr) 2008-01-11 2012-03-01 Hoffmann La Roche Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
EP2736920A1 (en) 2014-06-04
CN103732612A (zh) 2014-04-16
AU2012287251B2 (en) 2015-05-14
CO6862159A2 (es) 2014-02-10
JP2014527042A (ja) 2014-10-09
JO3148B1 (ar) 2017-09-20
EP2736920B1 (en) 2015-07-01
HUE027534T2 (en) 2016-11-28
EA201490161A1 (ru) 2014-04-30
AU2012287251A1 (en) 2014-01-30
ECSP14013179A (es) 2014-03-31
AP4080A (en) 2017-03-29
CR20140036A (es) 2014-03-21
AP2014007362A0 (en) 2014-01-31
ME02171B (me) 2015-10-20
ES2544937T3 (es) 2015-09-07
AR087107A1 (es) 2014-02-12
BR112014001600A2 (pt) 2017-02-21
IL229988A (en) 2017-07-31
KR20140026624A (ko) 2014-03-05
BR112014001600B1 (pt) 2022-09-13
JP6027110B2 (ja) 2016-11-16
PE20141061A1 (es) 2014-09-06
CY1116645T1 (el) 2017-03-15
MY184303A (en) 2021-03-31
PT2736920E (pt) 2015-09-16
MX2014001084A (es) 2014-02-27
TW201315732A (zh) 2013-04-16
DK2736920T3 (en) 2015-07-20
CL2014000175A1 (es) 2014-08-22
PH12014500215B1 (en) 2018-09-07
SI2736920T1 (sl) 2015-08-31
CA2841178A1 (en) 2013-01-31
WO2013016081A1 (en) 2013-01-31
CA2841178C (en) 2016-12-20
KR101578309B1 (ko) 2015-12-16
CN103732612B (zh) 2015-09-23
HRP20150771T1 (hr) 2015-08-28
TWI568730B (zh) 2017-02-01
US8569286B2 (en) 2013-10-29
MA35611B1 (fr) 2014-11-01
PH12014500215A1 (en) 2014-03-17
GT201400012A (es) 2014-07-16
US20130029972A1 (en) 2013-01-31
MX356536B (es) 2018-06-01
NZ618891A (en) 2015-12-24
EA023044B1 (ru) 2016-04-29
RS54135B1 (sr) 2015-12-31
HK1194086A1 (en) 2014-10-10
PL2736920T3 (pl) 2015-11-30

Similar Documents

Publication Publication Date Title
ECSP14013179A (es) Compuesto inhibidor de la señalización de la trayectoria notch
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
PE20150887A1 (es) Compuestos de benceno sustituidos
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
PE20151654A1 (es) Inhibidores de cdc7
UY33498A (es) Combinaciones de inhibidores de quinasas para el tratamiento de cancer
MX2018000916A (es) Derivados de benzodiazepina como inhibidores de rsv.
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
BR112014028042A2 (pt) inibidores de nampt
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
GT201300263A (es) Combinación de un inhibidor de cinasa de fosfatidilinositol-3 (pi3k) y un inhibidor de mtor
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
AR125339A2 (es) Compuesto inhibidor de la señalización de la trayectoria notch
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
ECSP099729A (es) Sales monoclorhidrato de un inhibidor de histona deacetilasa
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo